Lancet Infectious Diseases

Papers
(The H4-Index of Lancet Infectious Diseases is 120. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)
ArticleCitations
Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study1264
A minimal common outcome measure set for COVID-19 clinical research1154
A clinical case definition of post-COVID-19 condition by a Delphi consensus1112
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial1050
Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study938
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics931
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study897
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial891
Real estimates of mortality following COVID-19 infection856
Clinical features and management of human monkeypox: a retrospective observational study in the UK757
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study723
Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study648
The value of antimicrobial peptides in the age of resistance637
Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study628
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study579
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance568
COVID-19 and multisystem inflammatory syndrome in children and adolescents565
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study558
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study535
Genomic evidence for reinfection with SARS-CoV-2: a case study512
Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study474
Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study463
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2461
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, mult445
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study437
COVID-19 and medical education416
A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation413
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical 404
Stigma during the COVID-19 pandemic382
Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series355
The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries350
Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study350
Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study343
The many estimates of the COVID-19 case fatality rate341
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 335
Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study334
Risk of COVID-19 in health-care workers in Denmark: an observational cohort study332
Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis316
The COVID-19 infodemic305
Exaggerated risk of transmission of COVID-19 by fomites302
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial301
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison301
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression300
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study284
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial257
Serology testing in the COVID-19 pandemic response250
Pooling of samples for testing for SARS-CoV-2 in asymptomatic people249
Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study248
Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data244
Smell and taste dysfunction in patients with COVID-19242
Scaling up COVID-19 rapid antigen tests: promises and challenges239
Long-term consequences of COVID-19: research needs239
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study236
SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England235
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised232
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial230
Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT228
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial223
Changes in colistin resistance and mcr-1 abundance in Escherichia coli of animal and human origins following the ban of colistin-positive additives in China: an epidemiological comparative study223
The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis217
Willingness to vaccinate against COVID-19 in Australia216
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-cont212
Connecting clusters of COVID-19: an epidemiological and serological investigation210
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical tri203
COVID-19 in health-care workers in three hospitals in the south of the Netherlands: a cross-sectional study202
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study201
The global incidence and diagnosis of fungal keratitis199
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden194
Monitoring approaches for health-care workers during the COVID-19 pandemic194
Intention to vaccinate against COVID-19 in Australia192
Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis191
Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study191
The indirect impact of COVID-19 on women190
Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis185
Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and 185
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design184
Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study181
The important role of serology for COVID-19 control178
ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5177
Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial175
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial173
What reinfections mean for COVID-19168
Global shortage of personal protective equipment167
SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study167
Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis165
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wav165
Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis163
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape162
SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity161
SeroTracker: a global SARS-CoV-2 seroprevalence dashboard161
Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding160
Baricitinib for COVID-19: a suitable treatment?160
Utility of hyposmia and hypogeusia for the diagnosis of COVID-19156
Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study155
Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study154
Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study151
Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review150
Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis149
Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis146
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study145
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies142
Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study142
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial141
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial140
Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US138
Monkeypox outbreaks outside endemic regions: scientific and social priorities136
COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England136
Prevention of monkeypox with vaccines: a rapid review134
Monoclonal antibody therapies against SARS-CoV-2133
Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study133
China's successful control of COVID-19132
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial130
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study127
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial126
Bell's palsy and SARS-CoV-2 vaccines125
Concerns and motivations about COVID-19 vaccination125
SARS-CoV-2 and the human-animal interface: outbreaks on mink farms124
Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective obse124
Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB123
Hospitalisation among vaccine breakthrough COVID-19 infections121
0.10528683662415